000143013 001__ 143013
000143013 005__ 20240229112539.0
000143013 0247_ $$2doi$$a10.1097/CMR.0000000000000541
000143013 0247_ $$2pmid$$apmid:30653029
000143013 0247_ $$2ISSN$$a0960-8931
000143013 0247_ $$2ISSN$$a1473-5636
000143013 0247_ $$2altmetric$$aaltmetric:54125776
000143013 037__ $$aDKFZ-2019-00638
000143013 041__ $$aeng
000143013 082__ $$a610
000143013 1001_ $$0P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aSachpekidis, Christos$$b0$$eFirst author
000143013 245__ $$a18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
000143013 260__ $$a[s.l.]$$bOvid$$c2019
000143013 3367_ $$2DRIVER$$aarticle
000143013 3367_ $$2DataCite$$aOutput Types/Journal article
000143013 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681736506_12701
000143013 3367_ $$2BibTeX$$aARTICLE
000143013 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143013 3367_ $$00$$2EndNote$$aJournal Article
000143013 520__ $$aSixteen BRAF-mutation positive, metastatic melanoma patients with highly advanced disease received combination therapy of vemurafenib and ipilimumab as an individual treatment decision. Our aim was to assess the role of fluorine-18-fluorodeoxyglucose (F-FDG) PET/computed tomography (PET/CT) in the evaluation of the clinical benefit (CB) of this combination treatment. After clinical improvement under vemurafenib monotherapy, four cycles of ipilimumab were additionally administered. F-FDG PET/CT was performed before the start, after two cycles and after completion of the combined ipilimumab/vemurafenib treatment. PET-based patient response evaluation to treatment was based on the European Organization for Research and Treatment of Cancer and the PET Response Evaluation Criteria for Immunotherapy criteria. Progression-free survival (PFS) from the end of combination treatment was calculated. According to their best clinical response at the end of combination treatment, eight patients showed CB and eight patients had no-CB. Two patients revealed extraordinary good clinical outcome with PFS of more than 5 years. Overall, 13 out of 16 patients were correctly classified by the European Organization for Research and Treatment of Cancer and 15 out of 16 by the PET Response Evaluation Criteria for Immunotherapy criteria. Median PFS was 8.8 months among PET-responders and 3.6 months among nonresponders. During immunotherapy administration seven patients developed radiologic signs of immune-related adverse events (irAEs), with colitis and arthritis being the most frequent ones; these patients had a significantly longer PFS than those without irAEs (P=0.036). F-FDG PET/CT is a valuable tool for the evaluation of patients receiving a combination of targeted treatment and immunotherapy. The appearance of irAEs on PET/CT might correlate with benefit to immunotherapy.
000143013 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000143013 588__ $$aDataset connected to CrossRef, PubMed,
000143013 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b1
000143013 7001_ $$aHakim-Meibodi, Lara$$b2
000143013 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b3$$eLast author
000143013 7001_ $$aHassel, Jessica C$$b4
000143013 773__ $$0PERI:(DE-600)2030780-9$$a10.1097/CMR.0000000000000541$$gVol. 29, no. 2, p. 178 - 186$$n2$$p178 - 186$$tMelanoma research$$v29$$x0960-8931$$y2019
000143013 909CO $$ooai:inrepo02.dkfz.de:143013$$pVDB
000143013 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143013 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143013 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143013 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000143013 9141_ $$y2019
000143013 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000143013 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143013 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMELANOMA RES : 2017
000143013 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143013 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143013 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143013 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143013 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143013 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143013 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143013 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143013 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143013 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143013 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000143013 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000143013 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000143013 980__ $$ajournal
000143013 980__ $$aVDB
000143013 980__ $$aI:(DE-He78)E060-20160331
000143013 980__ $$aI:(DE-He78)C060-20160331
000143013 980__ $$aUNRESTRICTED